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3. Validation of the kinetic models by evaluating uraemic toxin
concentrations and co-morbidity variations after interventions (e.g.  
optimal dialysis strategy as determined by the modelling) in PD and HD 
patients.
4. Development of prediction simulator to determine the most optimal 
dialysis strategy in the individual patient, including the organisation of 
the ‘CKD academy’ for nephrologists and laboratory staff with workshops 
about the simulator and the related laboratory techniques.
Conceptualisation and validation of a paradigm based on uraemic toxins for management of 
chronic kidney disease in paediatric patients
Evelien Snauwaert1, Johan Vande Walle1,  Ann Raes1,  Wim Van Biesen2, Sunny Eloot2
Ghent University Hospital; 1Paediatric Nephrology, 2Nephrology
Paediatric Nephrology (3K12D) & Dialysis Unit Nephrology (1P8), Ghent University Hospital Ghent, BELGIUM – Contact: evelien.snauwaert@uzgent.be, sunny.eloot@ugent.be
By providing clinicians, dealing with children with CKD, with more advanced and appropriate tools to improve management of all children with CKD, i.e. better
assessment of the degree of renal dysfunction, better determination of the ideal time to start renal replacement therapy, and more accurate monitoring of the quality of
that renal replacement therapy, we aim to improve neurocognitive and psychosocial functioning, growth, maturation into puberty, and social integration and
survival.
Children with chronic kidney disease have significant co-morbidities resulting in 
 a lifelong need for health care
 3 times decreased life expectancy
 poor quality of life and integration in society
Good tools to evaluate severity and monitor adequacy of treatment of children 
with CKD are lacking resulting in suboptimal management. 
Retention of uraemic toxins is accepted to play a major role in the pathogenesis of 
the comorbid conditions, but studies in children are lacking. 
Background
The scientific objective of this four years project is to:
provide the clinician 
with new diagnostic and therapeutic tools 
for the management of children with chronic kidney disease
based on the improved understanding of 
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Calibration of the kinetic model 
by fitting on the in vivo data
Simulations with calibrated kinetic model
Calculation of TAC, TSR, Cpredialysis
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Development of the prescription simulator
In vivo validation of kinetic model:
Measuring TAC, TSR, Cpredialysis
in patients on different dialysis strategies
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• Patient characteristics
•Uraemic toxinmarker              
concentrations
Model parameters: 
V1, V2, K12
Cpredialysis
PD strategy: dwell time, 
PD fluid, APD/CAPD
HD strategy: 
sessions/week, session
duration, HD/HDF
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SIMULATION OUTPUT
New 
strategy: 
TAC
CpredialysisRelations between marker 
concentrations/ remova l, 
patient characteristics, and
PD strategies
1. Identify associations between concentrations of a broad array of
uraemic toxins and different co-morbidities: i.e growth, protein-
energy wasting, cardiovascular risk factors, quality of life, circadian
rhythm, psycho-social functioning (cross-sectional & longitudinal)
1. Evaluate kinetic modelling of uraemic toxin distribution and transport
in haemodialysis (HD) patients
IDENTIFICATION OF THE MOST 
REPRESENTATIVE URAEMIC TOXIN MARKER(S)
Methods 
